Healthy VolunteersPTSDAnxiety DisordersMedicinal Chemistry & Drug DevelopmentPersonality & Trait FactorsInterpersonal Functioning & Social ConnectednessMDMA

Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects

In a double-blind, randomised, placebo-controlled crossover study in 30 healthy males, a single 125 mg dose of MDMA given after conditioning enhanced rapid fear extinction and retention as indexed by reduced skin conductance responses to the conditioned stimulus, but had no effect on fear‑potentiated startle. MDMA raised plasma oxytocin levels and produced subjective effects linked to reduced CS+/CS− discrimination, though oxytocin itself did not predict extinction outcomes, suggesting MDMA may facilitate certain forms of learned fear attenuation relevant to its therapeutic use.

Authors

  • Patrick Vizeli
  • Matthias Liechti
  • Nikhil Varghese

Published

Frontiers in Pharmacology
individual Study

Abstract

Background

3,4-Methylenedioxymethamphetamine (MDMA) has shown initial promise as an adjunct in psychotherapy to treat posttraumatic stress disorder (PTSD). Its efficacy and safety have been demonstrated across phase I–III studies. However, the mechanism underlying the potential utility of MDMA to treat PTSD in humans has not yet been thoroughly investigated. Preliminary evidence suggests that MDMA may facilitate fear extinction recall, which may be through the release of oxytocin. To test this hypothesis, we examined the efficacy of acute MDMA treatment to enhance fear extinction learning and recall.

Methods

We used a two-period, double-blind, randomized, placebo-controlled crossover design in 30 healthy male subjects who received a placebo and a single dose of MDMA (125 mg). Fear extinction was tested using two separate Pavlovian fear conditioning paradigms, one using skin conductance response (SCR), and the other fear-potentiated startle (FPS) to conditioned cues. MDMA treatment occurred after fear conditioning and 2 h before extinction learning. Extinction recall was tested 23 h after MDMA intake. Additional outcome measures included subjective effects, emotion recognition tasks, plasma levels of oxytocin, and pharmacokinetics.

Results

Fear conditioning and extinction learning were successful in both fear extinction paradigms (generalized eta–squared [ges] for SCR: 0.08; FPS: 0.07). Compared to placebo treatment, MDMA treatment significantly reduced SCRs to the reinforced conditioned stimulus (CS+) during extinction learning (ges = 0.03) and recall (ges = 0.06). Intensity of the subjective effects of MDMA (good effect, trust, and openness) during extinction learning negatively correlated with the discrimination between CS+ and the safety stimulus (CS−) during recall. MDMA did not influence FPS to conditioned cues. Oxytocin concentration was increased fourfold on average by MDMA during acute effects but was not associated with fear extinction outcomes.

Conclusions

MDMA treatment facilitated rapid fear extinction and retention of extinction as measured by SCR to fear cues, in line with animal studies of MDMA facilitation of extinction. However, this effect may be limited to certain forms of learned fear responses, as it was not observed in the extinction model using startle reactivity as the outcome. This study provides further evidence for the facilitation of extinction with MDMA treatment and suggests this may be a component of its efficacy when paired with psychotherapy.Clinical

Available with Blossom Pro

Research Summary of 'Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects'

Introduction

MDMA is being investigated as an adjunct to psychotherapy for PTSD and social anxiety because it produces prosocial and anxiolytic subjective effects and alters emotion processing. Earlier research in animals and a small number of human studies suggested that MDMA may facilitate fear extinction or otherwise alter fear-memory processes, and oxytocin release has been proposed as one possible mediating mechanism. However, findings have been mixed across species and paradigms, and the mechanistic basis of MDMA's putative benefit in exposure-based therapies remains uncertain. Vizeli and colleagues set out to test whether a single acute MDMA dose enhances fear extinction learning and recall in healthy volunteers, and whether peripheral oxytocin release, MDMA plasma levels, or subjective effects predict any such enhancement. The investigators used two established human Pavlovian conditioning paradigms that index learned fear by skin conductance response (SCR) and by fear‑potentiated startle (FPS), employing a double‑blind, placebo‑controlled, crossover design with a 125 mg MDMA dose administered after acquisition and 2 h before extinction learning; extinction recall was tested the next day about 23 h after dosing.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (27)

Papers cited by this study that are also in Blossom

Effects of MDMA on attention to positive social cues and pleasantness of affective touch

Bershad, A. K., Mayo, L. M., Van Hedger, K. et al. · Neuropsychopharmacology (2019)

MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults

Danforth, A. L., Struble, C., Yazar-Klosinski, B. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)

MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms?

Feduccia, A. A., Mithoefer, M. C. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)

36 cited
Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.

Holze, F., Vizeli, P., Müller, F. et al. · Neuropsychopharmacology (2019)

214 cited
Role of the 5-HT2A receptor in acute effects of LSD on empathy and circulating oxytocin

Holze, F., Avedisian, I., Varghese, N. et al. · Frontiers in Pharmacology (2021)

Show all 27 references
Effects of a β-blocker on the cardiovascular response to MDMA (Ecstasy)

Hysek, C. M., Vollenweider, F. X., Liechti, M. E. · BMJ Open (2010)

47 cited
α₁-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans

Hysek, C. M., Fink, A., Simmler, L. D. et al. · Journal of Clinical Psychopharmacology (2013)

47 cited
MDMA enhances emotional empathy and prosocial behavior

´dric, C., Hysek, M., Schmid, Y. et al. · Social Cognitive and Affective Neuroscience (2013)

Effects of MDMA and Intranasal oxytocin on social and emotional processing

Kirkpatrick, M. G., Lee, R., Wardle, M. C. et al. · Neuropsychopharmacology (2014)

A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults

Maples-Keller, J. L., Norrholm, S. D., Burton, M. et al. · Journal of Psychopharmacology (2022)

42 cited
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)

Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies

Studerus, E., Vizeli, P., Harder, S. et al. · Journal of Psychopharmacology (2021)

50 cited
Safety pharmacology of acute MDMA administration in healthy subjects

Vizeli, P., Liechti, M. E. · Journal of Psychopharmacology (2017)

3,4-Methylenedioxymethamphetamine facilitates fear extinction learning

Young, M. B., Andero, R., Ressler, K. J. et al. · Translational Psychiatry (2015)

Cited By (11)

Papers in Blossom that reference this study

Psychedelic medicine: mechanisms, evidence, and translation to practice

Jacobs, E., Zahid, Z., Hinkle, J. et al. · BMJ (2026)

MDMA enhances positive affective responses to social feedback

Bershad, A. K., Hsu, D. T., De Wit, H. · Journal of Psychopharmacology (2024)

6 cited
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial

Mitchell, J., Ot’alora G, M., van der Kolk, B. et al. · Nature Medicine (2023)

399 cited
MDMA-assisted psychotherapy for PTSD: Growing evidence for memory effects mediating treatment efficacy

Sarmanlu, M., Kuypers, K. P. C., Vizeli, P. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2023)

Therapeutic mechanisms of psychedelics and entactogens

Heifets, B. D., Olson, D. E. · Neuropsychopharmacology (2023)

MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations

Kangaslampi, S., Zijlmans, J. · European Child and Adolescent Psychiatry (2023)

Show all 11 papers
Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder

Singleton, S. P., Wang, J. B., Mithoefer, A. T. et al. · Frontiers in Psychiatry (2023)

48 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

Effects of 3,4-Methylenedioxymethamphetamine on... — Research Summary & Context | Blossom